Twin Capital Management Inc. lifted its stake in Abbott Laboratories (NYSE:ABT – krásne ?ahko oteplené dámske koza?ky
ashevillewireless.org
buckeyeboerboels.com
fermelamarquise.com
krásne ?ahko oteplené dámske koza?ky
binkleytruck.com
stojalo za perilo vileda
ashevillewireless.org
emergencyplumbingpasadena.com
damske teplaky
buckeyeboerboels.com
kuffert tilbud
fermelamarquise.com
binkleytruck.com
cindyrodriguezcopywriting.com
Twin Capital Management Inc. Has $4.70 Million Stock Position in Abbott Laboratories (NYSE:ABT)
RegistrationCode=TickerHyperlink&Prefix=NYSE&Symbol=ABT”>Free Report) by 7.3% during the 4th quarter, HoldingsChannel reports. The fund owned 42,716 shares of the healthcare product maker’s stock after buying an additional 2,889 shares during the period. Twin Capital Management Inc.’s holdings in Abbott Laboratories were worth $4,702,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the business. Altshuler Shaham Ltd bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $28,000. Cornerstone Planning Group LLC bought a new position in shares of Abbott Laboratories in the second quarter valued at about $28,000. FWL Investment Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $33,000. True Wealth Design LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $33,000. Finally, Quarry LP grew its position in shares of Abbott Laboratories by 132.9% during the 2nd quarter. Quarry LP now owns 333 shares of the healthcare product maker’s stock worth $36,000 after buying an additional 190 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.
Abbott Laboratories Price Performance
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $9.96 billion for the quarter, compared to analyst estimates of $9.88 billion. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. Abbott Laboratories’s revenue was up 2.2% compared to the same quarter last year. During the same period last year, the firm posted $1.03 earnings per share. On average, equities analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be given a $0.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 2.10%. Abbott Laboratories’s dividend payout ratio is presently 67.48%.
Insider Transactions at Abbott Laboratories
In other news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at $2,223,060. The disclosure for this sale can be found here. Insiders sold 56,435 shares of company stock worth $6,451,298 over the last ninety days. 1.10% of the stock is owned by insiders.
Analyst Ratings Changes
Several equities analysts recently issued reports on ABT shares. Evercore ISI boosted their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Royal Bank of Canada dropped their price objective on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday. Raymond James upped their price objective on Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Barclays upped their price objective on Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Finally, TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, December 21st. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $121.31.
Read Our Latest Analysis on ABT
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Stories
- Five stocks we like better than Abbott Laboratories
- Learn Technical Analysis Skills to Master the Stock Market
- Comprehensive PepsiCo Stock Analysis
- Stock Dividend Cuts Happen Are You Ready?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Energy and Oil Stocks Explained
- 3 Steel Stocks Could Soar on New China Tariffs
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
